Carbohydrate-responsive element-binding protein (ChREBP), an activator of lipogenic and glycolytic pathways involved in NAFLD progression, is regulated by the HAT activator p300. Here, MLXIPL is linked to metabolic dysfunction-associated steatotic liver disease.